IQVIA Holdings Inc. Files 2024 10-K

TL;DR

IQVIA filed its 2024 10-K, check it for full FY results.

AI Summary

IQVIA Holdings Inc. filed its 2024 10-K on February 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Quintiles IMS Holdings, Inc., is a commercial physical and biological research services provider. Its principal executive offices are located at 2400 Ellis Road, Durham, NC.

Why It Matters

This filing provides a comprehensive overview of IQVIA's financial performance and business operations for the fiscal year 2024, offering insights for investors and stakeholders.

Risk Assessment

Risk Level: medium — The filing is a standard annual report and does not contain immediate red flags or significant new risks.

Key Numbers

• 2024 — Fiscal Year (Reporting period for the 10-K)
• 1231 — Fiscal Year End (Indicates the end of the reporting period)
• 20250213 — Filing Date (Date the 10-K was submitted to the SEC)

Key Players & Entities

• IQVIA HOLDINGS INC. (company) — Filer
• Quintiles IMS Holdings, Inc. (company) — Former Company Name
• 2400 ELLIS ROAD, DURHAM, NC 27703 (location) — Business Address
• 20241231 (date) — Fiscal Year End
• 20250213 (date) — Filing Date

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share IQV New York Stock Exchange
• $330 billion — We compete in a market of approximately $330 billion consisting of outsourced research and d
• $194 billion — drug development totaled approximately $194 billion in 2024. Of that amount, we estimate th
• $155 billion — preclinical spending) was approximately $155 billion. The portion of this addressable opport
• $73 billion — sed on our estimates, was approximately $73 billion. Real-World Evidence and connected he
• $85 billion — tal addressable market of approximately $85 billion in 2024 that consists of tightly couple
• $30 billion — or Real-World Evidence of approximately $30 billion includes post-launch evidence generatio
• $55 b — r connected healthcare is approximately $55 billion, and includes areas such as reven
• $82 billion — tal addressable market of approximately $82 billion in 2024 that includes information, data
• $1.73 — timated to have generated approximately $1.73 trillion in revenues in 2024. According

Filing Documents

• iqv-20241231.htm (10-K) — 3097KB
• ex-10361231202410xk.htm (EX-10.36) — 337KB
• ex-1911231202410xkxsecurit.htm (EX-19.1) — 61KB
• ex-2111231202410xk.htm (EX-21.1) — 248KB
• ex-2211231202410xk.htm (EX-22.1) — 18KB
• ex-231auditorconsent.htm (EX-23.1) — 2KB
• ex-3111231202410xk.htm (EX-31.1) — 9KB
• ex-3121231202410xk.htm (EX-31.2) — 9KB
• ex-3211231202410xk.htm (EX-32.1) — 6KB
• ex-3221231202410xk.htm (EX-32.2) — 6KB
• iqv-20241231_g1.jpg (GRAPHIC) — 4KB
• iqv-20241231_g2.jpg (GRAPHIC) — 150KB
• iqv-20241231_g3.jpg (GRAPHIC) — 66KB
• iqv-20241231_g4.jpg (GRAPHIC) — 9KB
• 0001478242-25-000045.txt ( ) — 18854KB
• iqv-20241231.xsd (EX-101.SCH) — 116KB
• iqv-20241231_cal.xml (EX-101.CAL) — 149KB
• iqv-20241231_def.xml (EX-101.DEF) — 660KB
• iqv-20241231_lab.xml (EX-101.LAB) — 1277KB
• iqv-20241231_pre.xml (EX-101.PRE) — 1039KB
• iqv-20241231_htm.xml (XML) — 3227KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS Except for any historical information contained herein, the matters discussed or incorporated by reference in this Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such forward-looking statements reflect, among other things, our current expectations, our forecasts and our anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "assumes," "anticipates," "believes," "estimates," "expects," "intends," "may," "forecasts," "plans," "projects," "should," "seeks," "sees," "targets," "will," "would" and similar words and expressions, and variations and negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We caution you that any such forward-looking statements are further qualified by important factors that could cause our actual operating results to differ materially from those in the forward-looking statements, including without limitation, that business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, international conflict or other disruptions outside of our control; most of our contracts may be terminated on short notice, and we may lose or ex

Business

Item 1. Business Our Company IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. We are committed to using artificial intelligence ("AI") responsibly, ensuring that our AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, we are dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. We are a global leader in protecting individual patient privacy. We use a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. We have one of the largest and most comprehensive collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales, prescription and promotional data, medical claims, electronic medical records, genomics, and social media. Our scaled and growing information

View Full Filing

View this 10-K filing on SEC EDGAR